• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    FDA Accepts Exelixis` NDA for Zanzalintinib + ICI in Cancer

    BUSINESSWIRE

    Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer

    PRESS RELEASE

    Exelixis Ph3 Data on Zanzalintinib Published in Lancet

    BUSINESSWIRE

    ESMO: Exelixis` TKI Reduces Risk Of Death By 20%

    FIERCE BIOTECH

    Exelixis Reports CABOMETYX Ph3 Lung, Thymic NET Results

    PHARMIWEB

    Adagene Expands SAFEbody Collab, License With Exelixis For 3 ADC

    GLOBENEWSWIRE

    Ipsen Gets EU OK for CABOMETYX in Neuroendocrine Tumors

    BUSINESSWIRE

    Exelixis: Zanzalintinib Combo Boosts OS in Colorectal Cancer

    BUSINESSWIRE

    Invenra Highlights Exelixis Phase 1 Study of XB628 in Solid Tumor

    BUSINESSWIRE

    Exelixis And Merck Sign Clinical Development Collaboration

    BUSINESSWIRE

    Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

    BUSINESSWIRE

    Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

    BUSINESSWIRE

    Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab

    BUSINESSWIRE

    Ajinomoto and Exelixis Enter Into Agreement to Develop Antibody-Drug Conjugates

    PR NEWSWIRE

    Novasep secures manufacturing deal with US biotech for ADC drug c

    CONTRACT PHARMA

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.